Publications
497 publications
- Date
- Relevance
-
Advice - do not reimburse loncastuximab tesirine (Zynlonta®) for the treatment of lymphoma
The National Health Care Institute has advised the Minister for Medical Care to not reimburse loncastuximab tesirine (Zynlonta®) ...
-
Advice - do not reimburse glofitamab (Columvi®) for the treatment of lymphoma
The National Health Care Institute has advised the Minister for Medical Care to not reimburse glofitamab (Columvi®) from the ...
-
Advice - reimburse pegunigalsidase alfa (Elfabrio®) for the treatment of Fabry disease
The National Health Care Institute has advised the Minister for Medical Care to reimburse pegunigalsidase alfa (Elfabrio®) from ...
-
Advice - reimburse benralizumab (Fasenra®) for the treatment of severe asthma
The National Health Care Institute has advised the Minister for Medical Care to reimburse benralizumab (Fasenra®) from the basic ...
-
Advice - reimburse midazolam nasal spray (Nasolam®) for the treatment of epilepsy
The National Health Care Institute has advised the Minister for Medical Care to reimburse midazolam nasal spray (Nazolam®) from ...
-
Advice - reimburse avalglucosidase alfa (Nexviadyme®) for the treatment of Pompe disease
The National Health Care Institute has advised the Minister for Medical Care to reimburse avalglucosidase alfa (Nexviadyme®), ...
-
Advice - reimburse efgartigimod alfa (Vyvgart®) for the treatment of myasthenia gravis
The National Health Care Institute has advised the Minister for Medical Care to reimburse efgartigimod alfa (Vyvgart®) from the ...
-
Advice - do not reimburse nivolumab-relatlimab (Opdualag®) for the treatment of skin cancer
The National Health Care Institute has advised the Minister of Health, Welfare and Sport (VWS) to not reimburse ...
-
Advice - conditional inclusion of pembrolizumab (Keytruda®) as an additional treatment of breast cancer prior to surgery
The National Health Care Institute has advised the Minister for Medical Care to reimburse pembrolizumab (Keytruda®) immunotherapy ...
-
Progress report on the conditional inclusion of orphan drugs, conditionals and exceptionals (progress report year 2023)
At the request of the Minister of Health, Welfare and Sport (VWS), the National Health Care Institute publishes an annual report ...